摘要
目的探讨多巴类制剂及多巴胺受体激动剂(普拉克索)等不同抗帕药物对伴有轻度认知功能障碍的帕金森病(PD)患者的影响。方法将120例伴有轻度认知功能障碍的PD患者按服药种类的不同,随机分为3组,即多巴制剂组、普拉克索组、多巴制剂联合普拉克索组。观察三组患者治疗1年后认知功能的变化,以及三组患者治疗前后运动能力和血浆Hcy水平的变化。结果治疗后,三组患者UPDRSⅢ评分均下降,差异有统计学意义(P<0.05);多巴制剂组患者血浆Hcy水平较治疗前明显增高,差异有统计学意义(P<0.05),其余两组血浆Hcy水平治疗前后没有明显变化。多巴制剂组MoCA评分治疗后较治疗前略有下降,但差异无统计学意义(P>0.05),普拉克索组MoCA评分治疗后较治疗前略增高,但差异无统计学意义(P>0.05),联合治疗组MoCA评分治疗后较治疗前明显增高,差异有统计学意义(P<0.05)。结论多巴制剂联合普拉克索可以改善PD合并轻度认知功能障碍患者的运动症状和认知功能,延缓痴呆的发生。
Objective To investigate the effects of dopamine preparations and dopamine receptor agonists(Praxol)on mild cognitive impairment in patients with Parkinson′s disease(PD).Methods Totally 120 patients with Parkinson′s disease complicated with mild cognitive impairment were randomly divided into three groups according to the type of medication:dopa preparation group(dopa group),Prac group,dopa preparation combined with Praxol group(combined group).The changes in cognitive function,motor ability and plasma Hcy level before and after one year of treatment in the three groups were observed.Results After treatment,the UPDRSⅢscore of the three groups decreased(P<0.05);the plasma Hcy level of dopa group was increased(P<0.05),but there was no significant difference in the other two groups before and after treatment(P>0.05).After treatment,the MoCA score of dopa group decreased slightly,while that of Prac group increased slightly,but there was no significant defference(P>0.05).The MoCA score of combined treatment group was significantly higher than that before treatment(P<0.05).Conclusion Doba preparation combined with Praxol can improve the motor symptoms and cognitive function of PD patients with mild cognitive impairment,and delay the occurrence of dementia.
作者
王一沙
吴琼
胡九娇
WANG Yi-sha;WU Qiong;HU Jiu-jiao(Department of Neurology,the Second Affiliated Hospital of Shenyang Medical College,Shenyang 110002,China;2017 Postgraduate of Shenyang Medical College,Shenyang 110034,China)
出处
《实用药物与临床》
CAS
2020年第5期447-450,共4页
Practical Pharmacy and Clinical Remedies
基金
沈阳市科技计划项目(18-014-4-66)。
